Browse By: Country ι Category ι Tag
Home  »  Therapeutic Area

Therapeutic Area Market Research Reports

More

Proton Therapy Market in Russia & Forecast, Reimbursement Policy, Patients Treated at Proton Therapy Centers
The untapped market of proton therapy in Russia would be more than US$ 3 Billion during forecast period. IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, has started installation of the Cyclone® 230 in 2016 for a new proton therapy center. The acceptance of the first treatment room is planned for the end of 2017. The proton therapy center in Dimitrovgrad will be IBA’s first in the Russian Federation and is expected to treat up to 1,200 patients per year according to IBA.   
Published Date: Mar 2017
Published By: Renub Research

Price: $1150
United States Proton Therapy Market & Forecast, Reimbursement Policy, Patients Treated at Proton Therapy Centers
The potential market of proton therapy in United States would be more than US$ 15 Billion by the end of 2021 and it is expected to grow with a CAGR of 6.04 percent in future. At present United States holds world’s 40 percent of Proton Beam Therapy Facility. In the recent time, more research institutes and hospitals are investing in proton therapy to make the technology more accessible to patients.
Published Date: Mar 2017
Published By: Renub Research

Price: $1200
Italy Proton Therapy Market, Patients Treated at Proton Therapy Centers & Forecast
Proton Therapy Market in Italy would double by the end of 2021 from its market in 2016. There are currently three proton therapy centers in Italy that significantly increases their capacity to treat more patients. In Italy the first patients were treated with proton beams in 2002 at the INFN-LNS, Catania.  Rising significant cancer incidence in Italy will further enhance the proton therapy market of Italy.
Published Date: Mar 2017
Published By: Renub Research

Price: $1150
Proton Therapy Market in Switzerland, Reimbursement Policy, Patients Treated at Proton Facility & Forecast
Switzerland has one of the old proton therapy centers in Europe and was established in 1984 and there are so many recommended proton therapy patients from other parts of Europe coming for their treatment. The old proton therapy center at CPT, PSI, Villigen was further renovated with technological advancement in 2010 and again in 2013. Switzerland Proton Therapy Market is expected to grow thrice from its present market in 2016. 
Published Date: Mar 2017
Published By: Renub Research

Price: $1150
Korea Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast
Korea Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast is a research study published by Renub Research. According to this research South Korea Proton Therapy Market is expected to almost triple by 2021 from its current market size in 2016. Untapped Proton Therapy Market for South Korea was more than 1 Billion USD in period of 2016. Proton Therapy plays an important role in delivering comprehensive cancer care to children and adults at the National Cancer Center of Korea (KNCC, IIsan). 
Published Date: Mar 2017
Published By: Renub Research

Price: $1150
United Kingdom (UK) Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Facility & Forecast
United Kingdom (UK) Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Facility & Forecast is a research study published Renub Research. UK Proton Therapy Market is expected to grow with a CAGR of 82% in future. United Kingdom Proton Therapy Market is expected to grow 10 times from its current market in 2016. Currently UK has only one Proton Therapy facility, at Clatterbridge cancer center and it’s a ‘low-energy’ machine, only suitable for treating people with rare eye cancers. 
Published Date: Feb 2017
Published By: Renub Research

Price: $1150
Global Magnesium Salicylate Market Research Report 2017
Production, means the output of Magnesium Salicylate Revenue, means the sales value of Magnesium Salicylate This report studies Magnesium Salicylate in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering Cigna New Roots Herbal ... Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Magnesium Salicylate in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast Asia India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided
Published Date: Feb 2017
Published By: QYResearch

Price: $2900
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also „freed“ tumor specific neoantigens, indirectly acting as a cancer vaccine.
Published Date: Jan 2017
Published By: La Merie Publishing

Price: $2400
Europe Uterine Fibroids Treatment Market Report 2017
This report studies sales (consumption) of Uterine Fibroids Treatment in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering
Published Date: Jan 2017
Published By: QYResearch

Price: $3900
China Uterine Fibroids Treatment Market Research Report 2017
This report studies Uterine Fibroids Treatment in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering
Published Date: Jan 2017
Published By: QYResearch

Price: $3200
Global Pruritus Therapeutics Market Research Report 2016
Production, means the output of Pruritus Therapeutics Revenue, means the sales value of Pruritus Therapeutics This report studies Pruritus Therapeutics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Brunswick Corporation Johnson Health Tech Co. Ltd Nautilus Strength Icon Health & Fitness Amer Sports Technogym Precor incorporated Cybex International Inc Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Pruritus Therapeutics in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan Southeast A
Published Date: Jan 2017
Published By: QYResearch

Price: $2900
COPD Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies
Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. COPD occurs most often in older people, but can also affect people in their middle ages. It is a major cause of chronic morbidity and mortality globally. Many people suffer from this disease for years, and die from it or its complications, and it constitutes a substantial economic and social burden.
Published Date: Jan 2017
Published By: GBI Research

Price: $4995
Dermatology Therapeutics Drug Development Pipeline Review, 2016
?Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.
Published Date: Dec 2016
Published By: GBI Research

Price: $3995
Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)
The report titled “Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)” provides an in-depth analysis of the global AAT Replacement Therapy market with detailed analysis of market sizing, growth and market share. The report provides market size by value and volume along with the supply trend prevailing in the market. The report provides detail market analysis of the major products available in the market for treating AAT deficiency. The four major products included are, Prolastin, Glassia, Zemaira, and Aralast. Among which, Prolastin had the monopoly in the market for over 25 years, Asit was the first AAT Replacement Therapy available in the market for the treatement. The report also assesses the key opportunities in the market and out
Published Date: Dec 2016
Published By: Daedal Research

Price: $800
Report Package: Hot targets for empowered antibody and cell therapy technologies
This package contains three reports analyzing BCMA, CD123 and CD22 as versatile and hot targets for the successful application of empowered antibody and cell technologies, including: Fc-Engineered Antibodies; Radioimmunotherapy;   Immunotoxins; Antibody-Drug Conjugates; T-Cell Redirecting Bispecific Antibodies; Chimeric Antigen Receptor (CAR) T-Cells. The reports describe and discuss Target background, scientific rationale & expression profiles; Preclinical proof-of-concept; Clinical experience; Competitive landscape; Drug or cell therapy profiles; Company profiles. Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices: B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities CD123:
Published Date: Dec 2016
Published By: La Merie Publishing

Price: $1254
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others
This Competitive Intelligence report about Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Othersevaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including IDO (Indoleamine 2,3-dioxygenase TDO ( Tryptophan 2,3 dioxygenase) TGF-B/R ( Transforming Growth Factor beta/Receptor) CXCR4(Chemokine Receptor Type 4) CSF-1R ( Colony Stimulating Factor-1 Receptor) CD47 – SIRPa (Signal Regulatory Protein Alpha) Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine STING (STimulator of INterferon Genes) Receptor Others ( e.g. arginase) Purchase of
Published Date: Dec 2016
Published By: La Merie Publishing

Price: $770
Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
?Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.
Published Date: Dec 2016
Published By: GBI Research

Price: $4995
Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy
Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother.
Published Date: Nov 2016
Published By: GBI Research

Price: $4995
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation
Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available. Current asthma treatment options are able to provide the majority of patients with a sufficient level of disease control. 
Published Date: Nov 2016
Published By: GBI Research

Price: $6995
South East Asia Allergy Immunotherapies Market Research Report 2021
This report studies sales (consumption) of Allergy Immunotherapy in Southeast Asia market, especially in Indonesia, Philippines, Thailand, Malaysia, Singapore and Vietnam, focuses on top players in these countries, with revenue and market share for each player in these regions, covering
Published Date: Sep 2016
Published By: QYResearch

Price: $4800

Back To Top